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Background: We derived estimates of overdiagnosis by polygenic risk groups and examined whether polygenic risk-stratified
screening for prostate cancer reduces overdiagnosis.
Methods: We calculated the polygenic risk score based on genotypes of 66 known prostate cancer loci for 4967 men from the
Finnish section of the European Randomised Study of Screening for Prostate Cancer. We stratified the 72 072 men in the trial into
those with polygenic risk below and above the median. Using a maximum likelihood method based on interval cancers, we
estimated the mean sojourn time (MST) and episode sensitivity. For each polygenic risk group, we estimated the proportion of
screen-detected cancers that are likely to be overdiagnosed from the difference between the observed and expected number of
screen-detected cancers.
Results: Of the prostate cancers, 74% occurred among men with polygenic risk above population median. The sensitivity was 0.55
(95% confidence interval (CI) 0.45–0.65) and MST 6.3 (95% CI 4.2–8.3) years. The overall overdiagnosis was 42% (95% CI 37–52)
of the screen-detected cancers, with 58% (95% CI 54–65) in men with the lower and 37% (95% CI 31–47) in those with higher
polygenic risk.
Conclusion: Targeting screening to men at higher polygenic risk could reduce the proportion of cancers overdiagnosed.
At 13 years of follow-up, the European Randomised Study of
Screening for Prostate Cancer (ERSPC) showed a 21% relative
reduction in prostate cancer mortality in favour of screening, with
one prostate cancer death prevented and 27 additional cases
detected per 781 men invited to screening (Schroder et al, 2014).
The number needed to detect and the number needed to invite to
prevent one prostate cancer death were less at 13 years than at 9
and 11 years of follow-up. Despite the improvement in the absolute
benefit of screening, concerns about the negative consequences of
screening, mainly overdiagnosis and treatment of overdiagnosed
cancers, remain obstacles for large-scale screening. An over-
diagnosed cancer is defined as one that would not have presented
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clinically in a person’s lifetime in the absence of screening.
Developing methods to reduce overdiagnosis remains crucial for
diminishing the adverse effects of screening.
To date, genome-wide association studies have identified 100
prostate cancer susceptibility loci, which explain B33% of the
familial risk of prostate cancer in population of European ancestry
(Al Olama et al, 2014). Assuming a log-additive model of
interaction between loci, the currently known loci define a
polygenic risk profile that could be used for risk stratification
(Pharoah et al, 2008; Pashayan et al, 2011). Men at 90th and 99th
percentile of the risk distribution are at 2.9- and 5.7-fold increased
risk for prostate cancer compared with the average population
(Al Olama et al, 2014).
A personalised screening strategy based on age and genetic risk
has the potential to improve the efficiency of the screening
programme (Pashayan et al, 2011) and reduce its adverse
consequences (Pashayan et al, 2015). A mathematical modelling
study using UK-based prevalent screen and incident cancer data
has shown that the proportion of screen-detected cancers likely to
be overdiagnosed varies inversely by polygenic risk (Pashayan et al,
2015). However, the estimates of overdiagnosis were based on
mean sojourn time (MST) and test sensitivity derived from the
published literature. Using screening trial data from the Finnish
section of ERSPC, this study aims to estimate MST and sensitivity
and then use these estimates to derive the probability of
overdiagnosis by polygenic risk. This is to examine whether a
risk-stratified screening strategy reduces the proportion of cancers
overdiagnosed.
MATERIALS AND METHODS
Study participants. The Finnish Prostate Cancer Screening Trial
is the largest component of the ERSPC. The trial population and
the protocol have been described in detail elsewhere (Finne et al,
2003). Briefly, during 1996 and 1999, a total of 80 458 men aged 55,
59, 63, and 67 years were identified from the Finnish Population
Registry and of whom 80 176 were randomised to either the
screening arm (N¼ 31 875) or the control arm (N¼ 48 301). Men
in the screening arm were invited for serum prostate specific
antigen (PSA) testing every 4 years up to three times until age 71
years. The study protocol was approved by the ethical committees
of Helsinki University Hospital and Tampere University Hospital.
Figure 1 presents the number of men in the trial and cancers
detected.
Men were referred for transrectal ultrasound-guided biopsy if
the PSA value wasX4.0 ngml 1 or the PSA was 3.0–3.99 ngml 1
with suspicious findings on digital rectal examination (in 1996–1998)
or with free/total PSA ratio o0.16 (since 1999). Initially, sextant
biopsies were used, and from 2002, 10 to 12 biopsy cores
were taken.
Incident cancers diagnosed among the controls and the non-
participants, and interval cancers were identified through record
linkage to the nationwide population-based Finnish Cancer
Registry, which has almost complete coverage of all solid cancers
diagnosed in Finland (Teppo et al, 1994). An interval cancer was
defined as cancer diagnosed in the interval 1-4 years after screening
attendance. Cancers in non-participants and in those diagnosed
more than 4 years after the previous screen were not regarded as
interval cancers. Cancers that were not diagnosed through
organised screening were referred to as clinically diagnosed.
Prostate cancer was classified as localised disease with tumour-
node-metastasis (TNM) stage T1-2 N0 M0; and advanced disease
(regional-distant) with stage T3 and above or any T N1 M1; as
non-aggressive tumour, Gleason scoreo7, and aggressive tumour,
Gleason score X7.
The follow-up for this analysis was until 31 December 2011 and
the median duration of follow-up was 13 years.
Genotyping and quality control. At the time of genotyping, there
were 70 prostate cancer susceptibility variants identified through
genome-wide association studies. The analysis was based on 66 of
these variants (Supplementary Table 1S) for a sample of the trial
participants, 1089 men with prostate cancer and 3878 men without
prostate cancer. Genotyping platform (Wang et al, 2009; Eeles et al,
2013) and quality control are described in the Supplementary File.
Polygenic risk score and absolute risk calculations. A polygenic
risk score (PRS) for each individual was calculated as:
PRSj ¼
Xn
i¼1
bixij ð1Þ
where bi is the per-allele log-odds ratio for locus i, xij represents the
number of risk alleles (i.e., 0, 1 or 2) carried by each individual j at
locus i, and n is the number of loci.
The risk conferred by each of the variants is assumed to be allele
dose-dependent with a multiplicative (log-additive) effect on a
relative-risk scale (Pharoah et al, 2002). Under the multiplicative
model the distribution of polygenic risk in the population at birth
follows the normal distribution when relative risk is plotted on a
logarithmic scale, with mean, m, and variance s2. We set the mean,
m ¼  s2/2, so that the mean relative risk in the population at
birth is equal to unity. The distribution of relative risk among cases
at young ages is also log-normal with the same variance, but with
larger mean, m þ s2 (Pharoah et al, 2002).
Estimating overdiagnosis
Mean sojourn time and sensitivity of PSA. Assuming exponential
distribution of sojourn time, we estimated the sensitivity and the
MST by the maximum likelihood method of Walter and Day
(Walter and Day, 1983). The likelihood was evaluated over a two-
dimensional grid of values of sensitivity, S, and of inverse of MST,
l. The observed incidence of interval cancers was assumed to
follow a Poisson process with an expected incidence of interval
cancer that depends on S and l, as such:
IintðtÞ ¼ Ið1SÞþIS tþ e
lt1
l
 
ð2Þ
where Iint(t) is the expected incidence rate of interval cancers at
time t, and I* is the underlying incidence rate of prostate cancer in
the absence of screening, derived from the observed incidence rate
in the control arm. Here, person-years at risk were calculated from
time of randomisation to time of prostate cancer diagnosis, death
or censoring date (31 December 2011), whichever occurred first.
To calculate the 95% confidence level (CI), we identified the
combinations of values of S and l for which the log likelihood was
1.92 less than the maximum value (Day and Walter, 1984).
As the maximum likelihood approach is based on interval
cancers, the derived estimates of S and l refer to non-over-
diagnosed cancers. Also, given how interval cancers were defined
in this study, the sensitivity refers to episode sensitivity,
that is, performance of the test and the diagnostic work up
(Hakama et al, 2007).
Expected number of non-overdiagnosed screen-detected cancers.
Given S and l, we estimated the expected prevalence and incidence
of non-overdiagnosed cancers at first and subsequent screens, as
such:
Expected prevalence:
P ¼ I
S
l
ð3Þ
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Expected incidence at second screen:
I01 ¼ IS
1Sð Þe4l
l
þ 1e
4l 
l
 
ð4Þ
Expected incidence at third screen:
I02 ¼ S
I01 1Sð Þ
S
þ I
 1e4l 
l
 
ð5Þ
We applied the expected prevalence and incidence rate to the
number of men screened at each round, and estimated
the expected number of non-overdiagnosed cancers. If O is the
observed number of screen-detected cancers, and E is the expected
number of non-overdiagnosed cancers, then the proportion of
screen-detected cancers likely to be overdiagnosed would be OEO .
Estimation of overdiagnosis by PRS. The PRS was available on
subsample of men with screen-detected cancers, interval cancers,
and incident cancers, and on subsample of men without cancer.
We stratified men with and without prostate cancer into two risk
groups: below and above 50th percentile of polygenic risk
distribution among the population, hereafter referred to as lower
and higher risk groups, respectively. In the subsamples, the
proportions in the higher risk groups are shown in Table 1. We
used these proportions as sampling fractions to derive the likely
proportion of the study population with and without prostate
cancer in the lower and higher risk groups. To estimate the
baseline incidence rate of prostate cancer by polygenic risk groups,
we derived the relative rate of clinical cancers in the two risk
groups using information on interval cancer as such:
Rh
Rl
¼ nh=Nh
nl=Nl
ð6Þ
where nh and nl are the number of interval cancers in the higher
and lower risk groups, respectively; and Nh and Nl are the number
of men screened in the higher and lower risk groups, respectively.
Then the overall rate would be:
I ¼ apRhþ 1ap
 
Rl ð7Þ
where apis the sampling fraction for men free of cancer in the
screening arm and in the higher risk group.
Identified from
population registry
Randomised
Screening arm
Never attended
Pca diagnosed
N = 80 458
N = 80 176
Control arm
N = 48 301
Pca diagnosed
N = 4 150
N = 31 875
Interval cancer-1
N = 200
Prevalence screen-
detected Pca
N = 686
Incident screen-
detected Pca
N = 596
Incident screen-
detected cancer
N = 364
Interval cancer-2
N = 212
Interval cancer-3
N = 113
Pca diagnosed*
N = 565
Attended one screening
round
N = 23 771
Attended 2 screening
rounds
N = 18 044
Attended 3 screening
rounds
N = 10 328
N = 6 430
N = 562
Never invited N = 1 674
Figure 1. Flow chart of the Finnish Prostate Cancer Screening Trial. *Cancer diagnosed more than 4 years since the last screen; 282 men were
excluded from randomisation because of death, or prostate cancer diagnosis. Pca, prostate cancer.
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We derived separate estimates of overdiagnosis for those in the
lower and higher risk groups by repeating the steps used to
estimate the overall overdiagnosis.
Sensitivity analysis. In the Finnish Prostate Cancer Screening
Trial, 19% of men in the control group had PSA test in the first 4
years. In a sensitivity analysis, we estimated the baseline incidence
rate after excluding men with cancer detected following PSA
testing, and re-estimated overdiagnosis by polygenic risk groups.
RESULTS
The distribution of PRS based on 66 prostate cancer susceptibility
loci had mean (scaled mean) of  0.16 ( 0.20) and variance of
0.40 among men with no prostate cancer and mean of 0.30 (0.20)
and variance of 0.40 among men with the cancer. There was no
statistically significant difference in the mean PRS of men with
screen-detected vs clinically diagnosed cancer (t-test P¼ 0.137)
(Table 2). The polygenic risk scores at the 25th, 50th, and 75th
percentiles of the risk distribution among men with no prostate
cancer accounted for 17%, 26%, and 48% of the cases, respectively.
Thus, men in the high-risk group (above the 50th centile)
accounted for 74% of the cases.
The PRS was available on 35% of men with screen-detected
cancer and 9% of men with cancer in the control arm. The
proportions of men with screen-detected cancer with advanced stage,
Gleason score X7, or PSA X4 were comparable between the trial
participants overall and the subsample of men with PRS. However,
out of clinically diagnosed cancers, the subsample with PRS had
lower proportion of cancers with advanced stage or Gleason score
X7 compared with all clinically diagnosed cancers (Table 3).
PSA level varied by polygenic risk, 18% of men in the higher
polygenic risk group compared with 7% of men in the lower risk
group had PSA Z4 ngml 1 (Po0.001). However, after adjusting
for stage and Gleason score, there was no statistically significant
association between polygenic risk group and PSA categories (odds
ratio¼ 1.35, 95% CI 0.89-2.04). Among the screen-detected
cancers, there was statistically significant association between
polygenic risk group and stage (P¼ 0.046) and Gleason score
categories (P¼ 0.005). However, similar association was not seen
among the clinically diagnosed cancers (Table 3).
Overall, higher polygenic risk was associated with significantly
increased odds of Gleason score X7 tumours (odds ratio¼ 1.56,
95% CI 1.15–2.10) but not with advanced stage (odds ratio¼ 1.36,
95% CI 0.85-2.16).
The baseline incidence rate of prostate cancer in the control
group was 6.17 cases per 1000 person-years (4150 cases/672 610
person-years from time of randomisation to censoring date). The
estimated baseline incidence rates of prostate cancer were 2.47 and
9.90 cases per 1000 person-years in the lower and higher risk
groups, respectively. The likelihood for the expected incidence rate
of interval cancers was maximised for sensitivity of 0.55 (95% CI
0.45-0.65) and l of 0.16 (95% CI 0.12-0.24) (Table 4).
Given these parameters, the expected number of screen-detected
non-overdiagnosed cancers after three rounds of screening would
be 950. As such 42% (95% CI 37-52; 696 out of 1646) of the
observed screen-detected cancers would likely be overdiagnosed
(Table 5).
The lower risk group would account for 50% of the screening
episodes (N¼ 26 186) in the trial and almost 26% of the observed
screen-detected cancers (N¼ 453). A baseline incidence of 0.00247,
S of 0.55 and l of 0.16, the expected number of non-overdiagnosed
cancers would be 191. Hence, 58% (95% CI 54-65; 262 out of 453)
of the screen-detected cancers in the lower PRS group would likely
be overdiagnosed.
The higher risk group would account for almost 50% of the
screening episodes (N¼ 25 957) in the trial and almost 74% of the
observed screen-detected cancers (N¼ 1193). Using baseline
incidence rate of 0.00990, S of 0.55 and l of 0.16, the expected
number of non-overdiagnosed cancers would be 756. Correspond-
ingly, 37% (95% CI 31-47; 437 out of 1193) of the screen-detected
cancers would likely be overdiagnosed.
At 13 years of follow-up, the overall overdiagnosed cases per
1000 men screened were 29, with 22 and 37 in the lower and higher
polygenic risk groups, respectively.
Targeting screening to men in the higher risk group would miss
191 non-overdiagnosed cancers, while avoiding 262 overdiagnosed
cancers. Targeted screening would reduce the overall cases
overdiagnosed in the population from 29 (696 out of 23 771) to
18 (437 out of 23 771) per 1000 men.
In a sensitivity analysis, after excluding 9129 from the control
group who had PSA test in the first 4 years and the expected
subsequent 946 cancer diagnoses, the baseline incidence rate of
Table 1. Proportion of the study population with PRS and of those in the higher risk group
No. (%) with PRS
No. (%) with PRS in the
higher risk group
Screening arm
Men with no prostate cancer N¼21 030 3877 (18.4) 1930 (49.8)
Screen-detected cancer at first round of screening N¼ 686 173 (25.2) 131 (75.7)
Screen-detected cancer at subsequent rounds of screening N¼ 960 406 (42.3) 285 (70.2)
Interval cancer N¼ 525 115 (21.9) 92 (80.0)
Clinically diagnosed cancer 44 years after last screen N¼565 34 (6.0) 25 (73.5)
Non-participants with clinically diagnosed cancer N¼562 22 (3.9) 17 (77.3)
Non-participants with no cancer diagnosis N¼ 7542 0 (0.0) 0 (0.0)
Control arm
Clinically diagnosed cancer N¼4150 339 (8.2) 250 (73.8)
No cancer N¼44 151 1 (0.0) 1 (100.0)
Abbreviation: PRS¼polygenic risk score.
Table 2. Polygenic risk distribution among men with and
without cancer in the Finnish screening trial
Mean
Scaled
meana Variance
Men without prostate cancer N¼3878  0.160 0.198 0.397
Men with prostate cancer N¼ 1089 0.299 0.198 0.401
Men with screen-detected cancer N¼ 579 0.272 0.172 0.394
Men with clinically detected cancer N¼ 510 0.329 0.229 0.408
Polygenic risk score is based on the known 66 prostate cancer susceptibility loci.
aBy setting the mean polygenic relative risk in the population equal to unity.
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prostate cancer in the control group was 5.87 cases per 1000
person-years (3204 cases/545 148 person-years from time of
randomisation to censoring date). With baseline incidence rate
of 0.00587, the S and l were derived as 0.52 and 0.16, respectively.
With these parameters, overall overdiagnosis was estimated as
47%, with 62% in the lower risk group and 37% in the higher risk
group.
DISCUSSION
This study, based on the Finnish prostate cancer screening trial
data, suggests that the proportion of screen-detected cancers that
are likely to be overdiagnosed is inversely related to polygenic risk,
that is, proportion overdiagnosed decreases with increase in
polygenic risk. The proportion of screen-detected cancers that
are likely to be overdiagnosed is estimated to be 37% lower in men
with polygenic risk higher than the average population risk than in
men with lower polygenic risk. In the Finnish population-based
screening trial with three rounds of screening, 31 700 screening
episodes would detect 1000 cancers in these men, of which 577
would likely be non-overdiagnosed and 423 overdiagnosed. A
polygenic risk-stratified screening programme would involve
polygenic profiling of all men for risk stratification. Then the
screening test, the PSA, would be offered to the strata of men above
a certain polygenic risk threshold. As such a subset of men are
offered PSA screening. Targeting screening to men in the higher
polygenic risk group is estimated to reduce screening episodes by
half while detecting 80% of the non-overdiagnosed cancers and
reducing overdiagnosed cancers by 38% at a cost of missing 20% of
the non-overdiagnosed cancers. That is, for every non-over-
diagnosed cancer not detected through screening, almost two
(37/20) overdiagnosed cases could be avoided.
We have reported similar inverse association between quartiles
of polygenic risk and overdiagnosis using different analysis
approach and using data from the UK on prevalence screening
and incident cancers only (Pashayan et al, 2015). However, the
study was limited by taking MST and test sensitivity values from
different sources. In this study, having randomised screening trial
Table 4. Summary of the estimates used to derive the proportion of overdiagnosis by polygenic risk groups
Overall Lower risk group Higher risk group 95% CI
Estimates used to derive expected number of screen-detected cancers
Sensitivity (S)a 0.55 0.55 0.55 0.45–0.65
Inverse of mean sojourn time (l)a 0.16 0.16 0.16 0.12–0.24
Baseline incidence rate (cases/person-years) (I*) 0.00617 0.00247b 0.00990c
Sampling fractions
No cancer (ap) 1.000 0.502 0.498
Prevalent screen-detected cancer 1.000 0.243 0.757
Incident screen-detected cancer 1.000 0.298 0.702
Interval cancer 1.000 0.200 0.800
aS and l were derived from data on men in the lower and higher risk groups combined.
bRl.
cRh.
Table 3. Comparison of Gleason score, stage, and PSA categories among men in the trial and men with PRS
No. of men
N (%)
No. of men with PRS
N (%)
P-value
(Z-test)
Lower risk group
N (%)
Higher risk group
N (%)
P value
(v2-square test)
Gleason score
Overall N¼ 7268 N¼1083 o0.001 N¼288 N¼ 795 0.004
Gleason score o7 3947 (54) 731 (68) 214 (74) 517 (65)
Gleason score X7 3321 (46) 352 (32) 74 (26) 278 (35)
Screen-detected N¼ 1643 N¼578 0.645 N¼163 N¼ 415 0.005
Gleason score o7 1204 (73) 416 (72) 131 (80) 285 (69)
Gleason score X7 439 (27) 162 (28) 32 (20) 130 (31)
Clinically diagnosed N¼ 5625 N¼505 o0.001 N¼125 N¼ 380 0.284
Gleason score o7 2743 (49) 315 (62) 83 (66) 232 (61)
Gleason score X7 2882 (51) 190 (38) 42 (34) 148 (39)
Stage
Overall N¼ 7448 N¼1089 o0.001 N¼289 N¼ 800 0.198
Localised stage 5970 (80) 973 (89) 264 (91) 709 (89)
Advanced stage 1448 (20) 116 (11) 25 (9) 91 (11)
Screen-detected N¼ 1646 N¼579 0.441 N¼163 N¼ 416 0.046
Localised stage 1508 (92) 538 (93) 157 (96) 381 (92)
Advanced stage 138 (8) 41 (7) 6 (4) 35 (8)
Clinically diagnosed N¼ 5772 N¼510 o0.001 N¼126 N¼ 384 0.891
Localised stage 4462 (77) 435 (85) 107 (85) 328 (85)
Advanced stage 1310 (23) 75 (15) 19 (15) 56 (15)
PSA at screening
Screening arm N¼ 23770 N¼4605 o0.001 N¼2142 N¼ 2463 o0.001
PSA o4 ngml1 19 908 (84) 4016 (87) 1989 (93) 2027 (82)
PSA X4ngml 1 3862 (16) 589 (13) 153 (7) 436 (18)
Abbreviations: PRS¼polygenic risk score; PSA¼prostate specific antigen.
BRITISH JOURNAL OF CANCER Polygenic risk and overdiagnosis
1090 www.bjcancer.com |DOI:10.1038/bjc.2015.289
data with information on interval cancers, we estimated simulta-
neously the MST and episode sensitivity for non-overdiagnosed
cancers and from them derived the probability of overdiagnosis in
the Finnish trial setting. This enhances the validity of our results. We
do acknowledge, however, that the present results rely on a number
of assumptions, and that they remain subject to considerable
uncertainty. There is a need for continued development of rigorous
methods of estimation of overdiagnosis, including reliable confidence
interval estimation and for further data on screened and unscreened
populations with polygenic risk measured.
Although the proportion of screen-detected cancers that are
likely to be overdiagnosed decreased with polygenic risk, the
absolute rate of overdiagnosis increased with polygenic risk. This is
because majority of the cancers (74%) occurred in the higher risk
group. Although screening was estimated to result in 67% more
overdiagnosed cancers in the higher compared with the lower risk
group (437 vs 262), it also resulted in almost 300% more non-
overdiagnosed cancers in the higher risk group (756 vs 191). Thus,
overdiagnosis in the higher risk group is estimated to be
substantially smaller as a proportion of screen-detected cancers,
and would be expected to be correspondingly smaller in proportion
to prostate cancer deaths avoided.
We have used the maximum likelihood method to estimate
MST of 6.2 years and episode sensitivity of 55%. All estimates of
MST and sensitivity are subject to both sampling variation and
uncertainty due to other sources such as the distributional
assumptions involved. Our estimates are within the 95% CI of
previously reported estimates. Wu et al (2012) using multistate
modelling with the same Finnish screening trial data have reported
MST of 7.7 (95% CI 6.0-10.7) years and episode sensitivity of 43%
(95% CI 35-51) for the first screening round and 60% (95% CI 48-72)
for the second round. Our estimate of overdiagnosis of 42% is in line
with the estimates from the ERSPC (Draisma et al, 2003). Our
analysis indicates that 2.9% of men screened with three rounds of
screen are likely to be overdiagnosed. This estimate is comparable to
that of Wu et al (2012) of 3.4% (95% CI 2.1-5.7). These figures are
also consistent with other studies (Etzioni et al, 2002; Telesca et al,
2008; Draisma et al, 2009; Loeb et al, 2014).
It is of interest to know whether the natural history of the cancer
varies by genetic risk. However, the relatively small number of
cases, particularly in the lower polygenic risk group, limited
precision of the sensitivity and MST estimates by polygenic risk
group. As the majority of the cancers were in the higher polygenic
risk group, then the estimated MST and sensitivity are likely to
reflect primarily those of that population. Preliminary analysis
suggests similar episode sensitivity and longer MST in the lower
polygenic risk group. MST varying by polygenic risk is plausible
given the observed association between Gleason score and PRS.
With longer sojourn time, we would expect higher overdiagnosis
(Draisma et al, 2009) in the lower risk group. Risk groups with
longer MST may be offered less-frequent screening. As such
studying variation of MST with PRS is important for designing
risk-tailored screening.
The subsample of men with genotyping data and clinically
diagnosed cancer had less-aggressive and less-advanced cancers
than the remaining participants diagnosed clinically. Less-aggres-
sive cancers were associated with lower PRS. If our subsample had
more aggressive cancers, then the proportion of interval cancers
and baseline incidence rate in the higher risk group would have
been larger, resulting in even lower estimate of overdiagnosis in the
higher risk group.
Also, a sensitivity analysis accounting for some of the effect of
contamination yielded almost similar results.
In this study, we have used only polygenic risk profile for
stratification. Further research is needed to study the benefits, the
harms, and cost-effectiveness of stratifying the population into
several risk strata based on polygenic risk combined with other risk
factors, such as age, family history, and baseline PSA (Loeb, 2012;
Roobol and Carlsson, 2013), and offering screening differentially
(different starting age, inter-screening interval, and screening
modality) to each population stratum.
In summary, polygenic risk-stratified screening for prostate
cancer could reduce the proportion of cancers overdiagnosed.
Targeting screening to men at higher polygenic risk could improve
the benefit to harm balance of screening.
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